BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

AngioDynamics (ANGO)AngioDynamicsClinical readout

Pivotal U.S. Data Show Sustained Oncologic Control and Safety Profile at 24 months Results Presented at AUA 2026 LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system,

Related news

ANGOAngioDynamics2026-06-17 12:30 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

EXELExelixis2026-06-22 12:00 EST

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

KYMRKymera2026-06-25 11:00 EST

Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

IDYAIDEAYA Biosciences2026-06-01 15:00 EST

IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO

BMEABiomea Fusion2026-08-24 11:00 EST

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

View all latest news

AngioDynamics

Vascular and Interventional Technology AngioDynamics develops medical technologies that restore blood flow, remove thrombus and treat selected tumors. Its portfolio is organized around higher-growth interventional platforms and a broader medical-device business. Mechanical Thrombectomy AlphaVac and AngioVac are mechanical aspiration...

Recent company news

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

ANGOAngioDynamics2026-07-14 10:00 EST

AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability

ANGOAngioDynamics2026-06-30 12:00 EST

AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026

ANGOAngioDynamics2026-06-17 12:30 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-05-28 17:25 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

Stock data

Close
15.75 USD
Market cap
453.68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States